Browse by all authors Browse By Author ID - Charles Wendling

Browse Results (4 results found)

Subscribe to the RSS feed for this result setSubscribe to the RSS feed for this result set

Refine

  Abstract Views File Downloads Thomson Reuters Web of Science Citation Count Scopus Citation Count Altmetric Score
Fassas, A. B. T., Sawyer, J., McCoy, J., Anaissie, E. J., Lee, C. K., Talamo, G., Wendling, C., Zangari, M., Van Rhee, F., Thertulien, R., Tricot, G. J. and Barlogie, B. (2003). Absence of hypodiploidy and/or chromosome 13 abnormalities (hypo-CA13) confers superior survival in multiple myeloma (MM) patients (pts): Interim analysis of total therapy (TT) II trial. In: 45th Annual Meeting of the American Society of Hematology, San Diego CA, United States, (684A-684A). 6-9 December 2003. 64   0
Munker, R., Cordova, C., Polk, P., Wendling, C. V., Sun, A. W. and Cardelli, J. A. (2007). Activity of tyrosine kinase inhibitors in multiple myeloma. In: Blood. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA, United States, (274B-274B). 8-11 December 2007. 40   0
Wendling, CV, Glass, J and Rigby, PG (2006). Inpatient pharmaceutical cost of hematological agents: A single center report.. In: BLOOD. 48th Annual Meeting of the American-Society-of-Hematology, Orlando FL, (469B-469B). DEC 09-12, 2006. 19   0
Anaissie, E. J., Jacobson, J., Fassas, A. B., Zangari, M., Thertulien, R., VanRhee, F., Talamo, G., Tricot, G., Wendling, C., Davis, C. K., Hollmig, K. and Barlogie, B. (2003). Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. In: 45th Annual Meeting of the American Society of Hematology, San Diego CA, United States, (454A-454A). 6-9 December 2003. 26   0